Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03631043 · ClinicalTrials.gov registry record · Early Phase 1
Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma
A Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT03631043: Completed Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03631043 is a Early Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03631043, a Early Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This early phase I trial studies the side effects of personalized vaccine in treating patients with smoldering multiple myeloma. Vaccines made from a person's blood and bone marrow may help the body build an effective immune response to kill cancer cells.
Interventions
- DRUG Lenalidomide
- BIOLOGICAL Vaccine Therapy
- PROCEDURE Biopsy Specimen Radiography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-12-21 |
| Est. Completion | 2025-12-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03631043
The ClinicalTrials.gov registry entry for NCT03631043 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lenalidomide is the first listed.
NCT03631043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03631043 about?
NCT03631043 is a clinical study titled "Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma". This early phase I trial studies the side effects of personalized vaccine in treating patients with smoldering multiple myeloma. Vaccines made from a person's blood and bone marrow may help the body build an effective immune response to kill cancer cells.
What is the current status of trial NCT03631043?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2018-12-21. Estimated completion is 2025-12-10.
What interventions are being tested in trial NCT03631043?
The interventions under investigation include: Lenalidomide (DRUG), Vaccine Therapy (BIOLOGICAL), Biopsy Specimen Radiography (PROCEDURE).
Who is sponsoring clinical trial NCT03631043?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.